Trombectomía percutánea como tratamiento para la tromboembolia de pulmón. A propósito de un caso / Percutaneous thrombectomy as a treatment for pulmonary embolism. Case report

Presentamos el caso de una mujer con diagnóstico de tromboembolia aguda sintomática provocada de riesgo intermedio-altocon posterior inestabilización hemodinámica, convirtiéndose en una embolia de alto riesgo que precisa tratamiento trombolíticourgente. Sin embargo, al presentar una escala BACS de 3 puntos, y tratarse de una paciente de alto riesgo de sangrado, sedecide realizar tratamiento mediante trombectomía percutánea. Así revisamos brevemente la bibliografía disponible actual-mente sobre el tema.(AU)

We present the case of a woman with a diagnosis of acute symptomatic provoked pulmonary embolism of intermediate-highrisk with subsequent hemodynamic inestabilization, turning into a high-risk embolism that requires urgent thrombolytic treat-ment. However, when presenting a 3-point BACS scale, and being a patient at high risk of bleeding, we decided to performtreatment by percutaneous thrombectomy. Thus we briefly review the currently available bibliography on the subject.(AU)

¿Es la ecografía pulmonar útil en el diagnóstico y seguimiento de las enfermedades intersticiales pulmonares difusas? / Is lung ultrasound useful in the diagnosis and follow-up of diffuse interstitial diseases?

Las enfermedades pulmonares intersticiales difusas (EPID) se consideran un grupo heterogéneo de patologías que comparten en su mayoría manifestaciones clínicas, radiológicas y funcionales. El diagnóstico de las EPID se basa en la combinación de información clínica y pruebas funcionales, radiológica mediante la tomografía axial computarizada de alta resolución (TCAR) y/o histológica. Sin embargo, el uso de la ecografía pulmonar en la patología intersticial está poco desarrollada, tanto en el screening como en el seguimiento. Realizamos una revisión de la literatura para determinar la utilidad y las limitaciones de la ecografía en dicha patología (AU)

Diffuse interstitial lung diseases (ILD) are considered a heterogeneous group of pathologies that mostly share clinical, radiological and functional manifestations. The diagnosis of ILD is based on the combination of clinical information and functional tests, radiological by high resolution computed tomography (HRCT) and / or histological. However, the use of lung ultrasound in interstitial pathology is poorly developed, both in screening and in follow-up. We conducted a literature review to determine the usefulness and limitations of ultrasound in this pathology (AU)

No es COVID todo lo que reluce / All that glitters is not covid

Se describe el caso de una paciente de 50 años que fue ingresada durante la pandemia de SARS-CoV-2 (COVID-19) por neumonía bilateral, atribuida a la infección por dicho virus. Sin embargo, tras realizar pruebas complementarias, se diagnostica una pieza dentaria localizada en fosa nasal como foco infeccioso del proceso. Se concluye con la necesidad de efectuar una correcta anamnesis para valorar otras posibles causas de neumonía durante la pandemia por SARS-CoV-2 (AU)

We describe the case of a 50-year-old patient who was admitted during the SARS-Cov-2 (COVID-19) pandemic for bilateral pneumonia, attributed to infection by this virus. However, after complementary tests, a tooth located in the nostril is diagnosed as an infectious focus of the process. It concludes with the need to carry out a correct anamnesis to assess other possible causes of pneumonia during the SARS-CoV-2 pandemic (AU)

Toxicidad pulmonar aguda grave secundaria al uso de infliximab biosimilar en un paciente con enfermedad de Crohn / Acute severe pulmonary toxicity due to biosimilar infliximab in a Crohn's disease patient

No disponible

A DNA methylation map of human cancer at single base-pair resolution.

Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination.

Técnicas de desenmascaramiento antigénico e inmunohistoquímica. Estudio dirigido a anticuerpos con especiales dificultades de inmunodetección / Antigenic unmasking techniques in immunohistochemistry

No disponible

[The long-term efficacy of fibrinolytic treatment in the acute phase of a myocardial infarct. A comparison with a control group]. / Eficacia a largo plazo del tratamiento fibrinolítico en la fase aguda del infarto de miocardio. Comparación con un grupo control.

BACKGROUND: The follow-up of patients with an acute myocardial infarction treated with fibrinolysis and that of patients treated with conventional therapy was analyzed. PATIENTS AND METHODS: The study cohort included: 1) 214 patients with a first acute infarction of < or = 4 hours and with < or = 70 years of age who participated in a randomized study comparing the effects of streptokinase (SK, n: 110) vs conventional treatment (control, n: 104), and 2) a total of 361 patients with a myocardial infarction of < or = 6 hours and < or = 75 years old treated with fibrinolytic agents. RESULTS: In-hospital mortality in the randomized study was 11% for the control group and 7% for the SK group, and 8.8% for the rest of patients treated with fibrinolysis. Mortality during follow-up in the randomized study (7.0 +/- 1.5 years) was 10.7% for the SK group and 19.3% for the control group. Ejection fraction was significantly lower in non survivors than in survivors (36.7% vs 50.8%, (p < 0.0001) and among patients with an ejection fraction < 50%, follow-up mortality was significantly lower in those with a complete recanalization (TIMI 3) than in those with an absent or incomplete recanalization (TIMI 0-2) (98% vs 22%). Follow-up mortality for the rest of patients treated with fibrinolysis (2.6 +/- 1.6 years) was 9%. CONCLUSIONS: 1) The reduction of in-hospital mortality by fibrinolysis appears to increase in the long-term follow-up, and 2) the long-term survival seems to be related not only to the left ventricular function but also to the extent of angiographic recanalization.